Agamree is as effective as traditional corticosteroids at preserving walking ability but carries a lower risk of side effects ...

Columnist Robin Stemple and others in the Western Pennsylvania chapter of the FSHD Society raised $85,000 for research toward ...

Sarepta said DMD treatments Amondys 45 and Vyondys 53 show 'positive and encouraging trends' even though a trial failed to ...

In an effort to improve his heart health, columnist Shalom Lim trials a new medication for his cardiomyopathy, a complication ...

Dosing has begun in a long-term extension study testing Satellos Bioscience’s experimental oral therapy SAT-3247 in men with ...

Whether it's transportation, education, or treatment, the more choices people with LGMD have, the better, says columnist.

Columnist Betty Vertin shares how she explained Duchenne muscular dystrophy to her sons, who received their DMD diagnosis at a young age.

Columnist Betty Vertin marks each success with Duchenne MD with the refrain, "Not today, Duchenne," but she dreads when "today" will come.

Columnist Betty Vertin doesn't often dwell on her caregiver grief, but sometimes she needs to embrace it and let it flow through her.

Use of the oral therapy BBP-418 appeared to improve walking ability and lung function in people with limb-girdle muscular dystrophy type 2i (LGMD2i) — characterized by muscle wasting at the shoulders ...

In a $12 billion deal, Novartis has agreed to acquire Avidity Biosciences, which is developing several treatments for ...

Histone deacetylase inhibitors are a treatment approach designed to work by blocking an enzyme that turns off gene activity. This may ultimately help by slowing muscle loss and disease progression.